Table 3.
EORTC-QLQ-C30 scores at baseline and follow-up stratified by cancer diagnosis (yes/no), and the difference between diagnosis groups
| Cancer | Not cancer | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Difference within groupa | Baseline | Follow-up | Difference within groupa | Differences between groups at baselineb | Differences between groups at follow-upb | Difference between intra difference in groupsb | ||||
| EORCT | n=125 | n=125 | p-value | n=549 | n=549 | p-value | p-value | ES c | p-value | ES c | p-value | ES c |
| Global Health/QL, mean (SD) | 53 (23) | 56 (27) | 0.19 | 53 (24) | 60 (25) | <0.001 | 0.95 | 0.01 | 0.24 | 0.13 | 0.08 | 0.16 |
| Functional scales, mean (SD) | ||||||||||||
| Physical functioning | 74 (24) | 70 (27) | 0.42 | 75 (23) | 76 (23) | 0.39 | 0.78 | 0.06 | 0.07 | 0.25 | 0.28 | 0.28 |
| Role functioning | 57 (35) | 56 (36) | 0.64 | 63 (34) | 68 (32) | <0.001 | 0.10 | 0.17 | <0.001 | 0.38 | 0.06 | 0.22 |
| Emotional functioning | 74 (21) | 73 (22) | 0.39 | 70 (24) | 75 (24) | <0.001 | 0.07 | 0.19 | 0.13 | 0.08 | <0.001 | 0.35 |
| Cognitive functioning | 84 (21) | 80 (23) | <0.01 | 79 (24) | 79 (22) | 0.35 | <0.01 | 0.25 | 0.59 | 0.03 | 0.001 | 0.33 |
| Social functioning | 82 (26) | 77 (30) | 0.06 | 79 (26) | 79 (28) | 0.44 | 0.11 | 0.11 | 0.62 | 0.08 | 0.03 | 0.22 |
| Symptom scales/items, mean (SD) | ||||||||||||
| Fatigue | 45 (31) | 44 (30) | 0.86 | 46 (28) | 40 (27) | <0.001 | 0.47 | 0.07 | 0.24 | 0.13 | 0.003 | 0.26 |
| Nausea and vomiting | 10 (17) | 11 (19) | 0.93 | 10 (17) | 8 (16) | <0.001 | 0.75 | 0.01 | 0.08 | 0.18 | 0.08 | 0.20 |
| Pain | 31 (31) | 30 (31) | 0.33 | 35 (32) | 32 (31) | <0.01 | 0.24 | 0.12 | 0.37 | 0.08 | 0.98 | 0.04 |
| Dyspnea | 27 (33) | 25 (30) | 0.52 | 22 (30) | 19 (27) | <0.01 | 0.12 | 0.17 | 0.02 | 0.24 | 0.63 | 0.04 |
| Insomnia | 31 (34) | 33 (33) | 0.53 | 34 (35) | 32 (33) | 0.31 | 0.39 | 0.09 | 0.88 | 0.01 | 0.30 | 0.12 |
| Appetite loss | 33 (38) | 32 (36) | 0.92 | 29 (35) | 23 (32) | <0.001 | 0.40 | 0.10 | 0.02 | 0.25 | 0.07 | 0.18 |
| Constipation | 15 (28) | 19 (30) | 0.47 | 15 (26) | 14 (25) | 0.32 | 0.59 | 0.01 | 0.12 | 0.18 | 0.26 | 0.19 |
| Diarrhea | 16 (27) | 14 (26) | 0.57 | 17 (28) | 14 (24) | <0.001 | 0.65 | 0.04 | 0.64 | 0.01 | 0.36 | 0.06 |
| Financial difficulties | 5 (15) | 9 (18) | <0.01 | 9 (24) | 11 (25) | 0.04 | 0.07 | 0.20 | 0.94 | 0.09 | 0.13 | 0.12 |
Bold values show statistical differences within and between groups
aWilcoxon signed-rank test
bWilcoxon rank sum test
cEffect size (ES) estimated by Cohen’s d; <0.20 = none, 0.20–0.49 = small, 0.50–0.79 = moderate, ≥0.80 = large